Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of$ 0.31. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 48.39%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.34 per share when it actually produced a loss of $0.38, delivering a surprise of -11.76%.Over the last four quarters, the ...